Cargando…

Obstacles against the Marketing of Curcumin as a Drug

Among the extensive public and scientific interest in the use of phytochemicals to prevent or treat human diseases in recent years, natural compounds have been highly investigated to elucidate their therapeutic effect on chronic human diseases including cancer, cardiovascular disease, and neurodegen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassanzadeh, Kambiz, Buccarello, Lucia, Dragotto, Jessica, Mohammadi, Asadollah, Corbo, Massimo, Feligioni, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554750/
https://www.ncbi.nlm.nih.gov/pubmed/32927725
http://dx.doi.org/10.3390/ijms21186619
_version_ 1783593846722002944
author Hassanzadeh, Kambiz
Buccarello, Lucia
Dragotto, Jessica
Mohammadi, Asadollah
Corbo, Massimo
Feligioni, Marco
author_facet Hassanzadeh, Kambiz
Buccarello, Lucia
Dragotto, Jessica
Mohammadi, Asadollah
Corbo, Massimo
Feligioni, Marco
author_sort Hassanzadeh, Kambiz
collection PubMed
description Among the extensive public and scientific interest in the use of phytochemicals to prevent or treat human diseases in recent years, natural compounds have been highly investigated to elucidate their therapeutic effect on chronic human diseases including cancer, cardiovascular disease, and neurodegenerative disease. Curcumin, an active principle of the perennial herb Curcuma longa, has attracted an increasing research interest over the last half-century due to its diversity of molecular targets, including transcription factors, enzymes, protein kinases, growth factors, inflammatory cytokines, receptors, and it’s interesting pharmacological activities. Despite that, the clinical effectiveness of the native curcumin is weak, owing to its low bioavailability and rapid metabolism. Preclinical data obtained from animal models and phase I clinical studies done in human volunteers confirmed a small amount of intestinal absorption, hepatic first pass effect, and some degree of intestinal metabolism, might explain its poor systemic availability when it is given via the oral route. During the last decade, researchers have attempted with new pharmaceutical methods such as nanoparticles, liposomes, micelles, solid dispersions, emulsions, and microspheres to improve the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with a varying range of enhanced bioavailability. This manuscript critically reviews the available scientific evidence on the basic and clinical effects and molecular targets of curcumin. We also discuss its pharmacokinetic and problems for marketing curcumin as a drug.
format Online
Article
Text
id pubmed-7554750
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75547502020-10-14 Obstacles against the Marketing of Curcumin as a Drug Hassanzadeh, Kambiz Buccarello, Lucia Dragotto, Jessica Mohammadi, Asadollah Corbo, Massimo Feligioni, Marco Int J Mol Sci Review Among the extensive public and scientific interest in the use of phytochemicals to prevent or treat human diseases in recent years, natural compounds have been highly investigated to elucidate their therapeutic effect on chronic human diseases including cancer, cardiovascular disease, and neurodegenerative disease. Curcumin, an active principle of the perennial herb Curcuma longa, has attracted an increasing research interest over the last half-century due to its diversity of molecular targets, including transcription factors, enzymes, protein kinases, growth factors, inflammatory cytokines, receptors, and it’s interesting pharmacological activities. Despite that, the clinical effectiveness of the native curcumin is weak, owing to its low bioavailability and rapid metabolism. Preclinical data obtained from animal models and phase I clinical studies done in human volunteers confirmed a small amount of intestinal absorption, hepatic first pass effect, and some degree of intestinal metabolism, might explain its poor systemic availability when it is given via the oral route. During the last decade, researchers have attempted with new pharmaceutical methods such as nanoparticles, liposomes, micelles, solid dispersions, emulsions, and microspheres to improve the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with a varying range of enhanced bioavailability. This manuscript critically reviews the available scientific evidence on the basic and clinical effects and molecular targets of curcumin. We also discuss its pharmacokinetic and problems for marketing curcumin as a drug. MDPI 2020-09-10 /pmc/articles/PMC7554750/ /pubmed/32927725 http://dx.doi.org/10.3390/ijms21186619 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hassanzadeh, Kambiz
Buccarello, Lucia
Dragotto, Jessica
Mohammadi, Asadollah
Corbo, Massimo
Feligioni, Marco
Obstacles against the Marketing of Curcumin as a Drug
title Obstacles against the Marketing of Curcumin as a Drug
title_full Obstacles against the Marketing of Curcumin as a Drug
title_fullStr Obstacles against the Marketing of Curcumin as a Drug
title_full_unstemmed Obstacles against the Marketing of Curcumin as a Drug
title_short Obstacles against the Marketing of Curcumin as a Drug
title_sort obstacles against the marketing of curcumin as a drug
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554750/
https://www.ncbi.nlm.nih.gov/pubmed/32927725
http://dx.doi.org/10.3390/ijms21186619
work_keys_str_mv AT hassanzadehkambiz obstaclesagainstthemarketingofcurcuminasadrug
AT buccarellolucia obstaclesagainstthemarketingofcurcuminasadrug
AT dragottojessica obstaclesagainstthemarketingofcurcuminasadrug
AT mohammadiasadollah obstaclesagainstthemarketingofcurcuminasadrug
AT corbomassimo obstaclesagainstthemarketingofcurcuminasadrug
AT feligionimarco obstaclesagainstthemarketingofcurcuminasadrug